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1 |  INTRODUCTION
Type 2 diabetes and its related complications are major con-
tributors to disability, health care utilisation, expense and 
mortality.1 The increasing prevalence of type 2 diabetes is 
primarily related to increasing levels of obesity, reduced 
physical activity and ageing.2 No country to date has reversed 
its obesity epidemic,3 and Ireland is no exception with the 
percentage of adults who are obese increasing from 10% in 
1998 to 23% in 2018.4,5 There are limited current or historic 
data available on the epidemiology of diabetes in Ireland.6- 8 
Ireland does not have a national diabetes register, the epide-
miological data available being based on a number of rep-
resentative surveys undertaken at various time points. The 
information available indicates that the age- adjusted preva-
lence of diabetes increased substantially from 1998 to 2015.6
The health care cost of type 2 diabetes is primarily driven 
by the development of the so- called complications of the 
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Abstract
Aims: Type 2 diabetes is a major public health issue that has a large effect on soci-
ety including its health and social services. The aims of this paper are to generate a 
projection of the number of cases and explore the potential impact of a preventive 
intervention targeted at people with pre- diabetes on disease prevalence, complica-
tions, mortality and cost.
Methods: A Markov simulation model of diabetes and pre- diabetes in Ireland, for 
the period 1991 to 2036, was generated based on international epidemiological data. 
The simulation was calibrated with the available Irish data on the prevalence of pre- 
diabetes, diabetes and diabetic complications. The economic and health impact of a 
hypothetical nationwide preventive intervention programme, which reduces the in-
cidence by a factor consistent with the international literature, was estimated under 
three scenarios of alternative effectiveness and uptake.
Results: The estimated number of people over 40 years of age with type 2 diabetes in 
Ireland is projected to increase from 216,000 in 2020 to 414,000 in 2036. A preven-
tion programme, based on the NHS Diabetes Prevention Programme, is estimated 
to result in a reduction of between 2000 (0.5%) and 19,000 (4.6%) in the number of 
prevalent cases of diabetes in 2036 resulting in substantial health and quality of life 
benefits.
Conclusions: A wide range of initiatives with uncertain outcomes will be required to 
reduce the impact of obesity and type 2 diabetes. A diabetes prevention programme 
seems likely to be worth pursuing as one element of this set of initiatives.
K E Y W O R D S
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disease.1 Reducing the incidence of diabetes complications, 
a state where quality of life is significantly impacted, can be 
achieved by one or more of three broad approaches.
The first approach is to reduce the incidence of complica-
tions in people with diabetes through screening for the con-
dition and earlier detection of complications, for example, 
through the National Diabetic Retinal Screening programme.9 
This, combined with target- driven management of glucose, 
blood pressure and lipid levels, can reduce the incidence and 
impact of diabetic complications. Recent changes in the reim-
bursement of general practitioners (GPs) in Ireland for chronic 
disease management10 and structured care for diabetes11 aim to 
reduce the incidence and progression of diabetic complications 
through better management of the disease.
The second approach is to reduce the incidence of type 2 di-
abetes through targeted interventions aimed at people who have 
pre- diabetes. This is a cohort with a higher risk of developing 
type 2 diabetes for whom preventive efforts may be particularly 
valuable. This approach is currently being delivered in England 
with the NHS Diabetes Prevention Programme.12 Ireland does 
not currently have a national diabetes prevention programme 
targeted at people with pre- diabetes. Plans are in place to pilot 
a diabetes prevention programme in 2021; this will be linked to 
the new GP contract for chronic disease management that calls 
for screening for type 2 diabetes among individuals known to be 
at increased risk. A range of trials have demonstrated the effec-
tiveness of diabetes prevention programmes; a recent review of 
prevention programmes found an average reduction of 26% to 
29% in the incidence of type 2 diabetes.13 However, there is still 
considerable uncertainty and scepticism on the effectiveness of 
widespread implementation of such programmes.14 Much of 
the available evidence is based on idealised conditions using 
self- selecting individuals over short periods.15 Attendance rates 
are a key determinant of the impact that such programmes can 
have on reducing the national burden of diabetes. Attendance 
rates have been shown to be low in the United Kingdom and the 
United States where these programmes have been rolled out to 
the general population.16,17
The third approach to reducing the burden of diabetes on 
society is to reduce the incidence of type 2 diabetes through 
population- wide policies. These include taxes, subsidies, regu-
lations (e.g., food marketing), changes to the physical environ-
ment and population- wide health promotion policies.18 Recent 
examples of this approach in Ireland include the ‘The Healthy 
Ireland’ programme and the tax on sugar- sweetened beverages 
introduced in 2018. However, there is limited guidance from 
the literature on the potential impact population- wide policies 
might have on reducing the incidence of diabetes.19
Previous modelling exercises in Europe and the United 
States have shown the potential impact of alternative scenar-
ios and policies on the projected prevalence and impact of 
diabetes.19- 22 Jones et al. 20 show that more intensive man-
agement of diabetes and pre- diabetes can slow the growth in 
mortality due to diabetes. However, a substantial reduction in 
the prevalence of obesity in the population is required to re-
duce diabetes- related mortality. Gregg et al. 19 show a similar 
impact for targeted and population- wide approaches individ-
ually and that a combined strategy of population and targeted 
interventions is likely to have the largest effect on reducing 
the prevalence of diabetes.
In this study, we show the potential impact of a diabe-
tes prevention programme, similar to the programme im-
plemented in the United Kingdom, on the number of cases 
of diabetes (complicated and uncomplicated) and on the as-
sociated quality adjusted life years (QALYs) for the whole 
population. We also estimate the budgetary implications 
for the health service of introducing a diabetes prevention 
programme. The potential impact of a diabetes prevention 
programme is demonstrated by simulating a wide range of 
possible trajectories for the numbers of people with diabe-
tes and pre- diabetes based on the international literature. 
Projections are generated based on a range of possible future 
trends and alternative scenarios for the effectiveness and up-
take of a diabetes prevention programme.
2 |  METHODS
2.1 | Model overview
A time- discrete Markov model is used to simulate the num-
ber of people in each of five states— normoglycaemic, 
What's new?
• There are limited current or historic data available 
on the epidemiology of type 2 diabetes in Ireland.
• Randomised controlled trials of targeted diabetes 
prevention programmes have been shown to be ef-
fective. There is limited evidence available on the 
effectiveness of population- wide diabetes preven-
tion programmes.
• This study uses simulation methods to generate 
projections of the number of cases of diabetes and 
pre- diabetes in Ireland.
• The study shows that the impact of a diabetes pre-
vention programme will be strongly influenced by 
attendance rates.
• A diabetes prevention programme (on its own) 
will not stop the rise in the number of cases of di-
abetes— a broad suite of population- wide policies 
aimed at reducing obesity is likely to be required 
in addition to a diabetes prevention programme.
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pre- diabetes, uncomplicated diabetes, complicated diabetes 
and death— between 1991 and 2036. A macro- simulation 
approach was chosen for its transparency compared with a 
complex micro- simulation approach. In line with the NHS 
Diabetes Prevention Programme, the definition of pre- 
diabetes used in this study is having a glycated haemoglobin 
(HbA1c) of 42– 46 mmol/mol (6.0%– 6.4%). Figure 1 shows 
the five states of the model and the flows between these 
states.
The aim of the simulation is to firstly generate a projection 
of the potential future trajectory of the number of cases in 
Ireland. Alternative scenarios are then generated to estimate 
the potential impact of a diabetes prevention programme over 
the projection period.
Single- year age cohorts between 40 and 98 years of age 
are modelled for each state; a minimum age of 40 years was 
used, as this is when the incidence of type 2 diabetes typically 
begins to increase.23 The flows between states are determined 
by the number of people in each state and the transition rates 
between states. Men and women are modelled separately— 
transition rates are allowed to vary across sexes.
Detailed input data definitions, sources and values for 
the initial cohort sizes and transition rates between cohorts 
are listed in Table S1 in the Supplementary file. The size of 
all the initial cohorts are sourced from the 1991 census. The 
size of the 40- year- old age cohorts in each year is sourced 
from historic population estimates and projections from the 
national statistics office. The prevalence rates for each of the 
states for the original cohorts in 1991 and the new cohorts 
entering the model are sourced from the literature.
Transition rates between states were identified from the 
international literature. There is limited available informa-
tion in the literature for some of the transition rates, such as 
the incidence of pre- diabetes by age group, and the available 
rates do not always cover the time period (1991 to 2019). In 
addition, the transition rates from the literature are for coun-
tries that may have a different experience of diabetes. For 
these reasons, a range for each of the transition rate param-
eter values is specified based on the values identified in the 
literature. For a given replication, values for each parameter 
are selected at random from the specified range for each pa-
rameter; 2000 replications of the simulation are generated. 
Each replication yields a possible trajectory for the number 
of people in each state. Simulations were generated using R 
v3.6 and the Heemod package24; fanplots were created using 
the fanplot package.25
2.2 | Calibration
A two- stage calibration procedure is used to identify which of 
the simulation replications, and hence parameter value sets, 
are more credible. The first stage of the calibration procedure 
identifies which of the replications generate case numbers 
that are inconsistent with what we already know about the 
prevalence of diabetes and pre- diabetes in Ireland. A replica-
tion is deemed to be inconsistent with the observed preva-
lence data if the estimated number of cases of pre- diabetes 
or diabetes is outside a specified range or the proportion of 
people with diabetes with a complication is outside a speci-
fied range, as described below. This process allows a sub-
set of replications, with corresponding parameter values, to 
be identified that are consistent with what we know about 
the epidemiology of diabetes in Ireland. The specified range 
for the number of cases of pre- diabetes was sourced from 
a nationally representative survey carried out in 2007.7 The 
specified range for the number of cases of diabetes, and the 
proportion of these with a complication related to diabetes, 
was sourced from a nationally representative survey of peo-
ple over 50 years of age (TILDA) carried out in 2010/2011.26 
The 95% confidence intervals of prevalence estimates from 
these studies were used to calculate a range of estimates of 
diabetes and pre- diabetes for the study year.
The second stage of the calibration procedure is applied to 
the subset of replications identified as being consistent with 
the calibration points in the first stage. This stage compares 
the age distribution of the modelled cohorts with the ob-
served age distribution for each of the five census years.1 
Each replication is weighted based on the inverse of the dif-
ference between the number of people in each modelled age 
cohort and number of people in that cohort in the census. 
This ensures that aggregate mortality in the model is in line 
with observed mortality rates. The calibration procedure is 
outlined in more detail in the Supplementary File.
 11996, 2001, 2006, 2011 and 2016.
F I G U R E  1  Model structure. IC, inflow to complications state; IP, 
inflows to pre- diabetes; IU, inflow to uncomplicated diabetes; M, base 
mortality; MC, complicated diabetes mortality; MU, uncomplicated 
diabetes mortality; OP, outflows from pre- diabetes state to normal 
glucose state.
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2.3 | Projection period
Projections under four scenarios are generated. The first sce-
nario assumed that no diabetes prevention programme was 
implemented. Four alternative scenarios show the potential 
impact of a diabetes prevention programme introduced in 
2022. The scenarios assume different levels of effectiveness 
of the intervention, different durations of effectiveness and 
different attendance rates. The intervention effect is mod-
elled as a percentage reduction in the transition rate from 
pre- diabetes to diabetes, applied equally to all age cohorts:
where iuit is the transition rate from pre- diabetes to diabetes for 
each cohort i for time t. The scenarios are shown in Table 1 
and outlined in detail in the Supplementary File. For example, 
Scenario 2 is based on a reduction in the transition rate from 
pre- diabetes to diabetes of 26%; an intervention whose effects 
last for 4 years; and an attendance rate of 4.0% of people with 
pre- diabetes per year, in line with anticipated NHS Diabetes 
Prevention Programme attendance. The final column in Table 1 
shows the reduction in the aggregate transition rates for each 
scenario. The aggregate transition rate from pre- diabetes to dia-
betes is reduced by between 1.0% and 12.5% under the various 
scenarios.
Data sources for the cost of excess health care utilisa-
tion and programme costs are outlined in Table S1 in the 
Supplementary File. The cost of excess health care utilisa-
tion would be altered by changes in screening and treatment 
regimens employed. Productivity losses associated with pre-
mature death/retirement, absenteeism due to sick leave and 
presenteeism due, for example to retinopathy, are omitted 
from calculations. The intervention and health care costs are 
assumed to increase at a rate of 4.2% in line with the current 
rate of medical inflation.
In all scenarios, underlying trends in the incidence of pre- 
diabetes and mortality are selected at random from a range. 
The maximum trend in these variables is set at the top of 
the search range used in the calibration procedure outlined 
above. The minimum trend is set to zero; that is, the age- 
adjusted incidence of pre- diabetes remains stable, and there 
are no further improvements in mortality rates. The transition 
rate from pre- diabetes to diabetes, the incidence of complica-
tions and relative mortality rates are all assumed to remain 
stable. The assumptions applied for each time period are out-
lined in detail in Table S1.
3 |  RESULTS
Figure 2a,b shows the distribution of the estimated number 
of people with pre- diabetes and diabetes from 1991 to 2036 
obtained from the simulation models under Scenario 1 (no di-
abetes prevention programme). The weighted average num-
ber of people with diabetes is shown in blue. These figures 
show the dramatic rise in the number of people with diabetes 
in Ireland driven by a combination of a growing and age-
ing population and increases in the incidence of pre- diabetes. 
We estimate that the number of people with diabetes (pre- 
diabetes) will increase from 216,000 (192,000) in 2020 to 
414,000 (303,000) in 2036 in the absence of a prevention 
programme. This corresponds to a prevalence of diabetes 
(pre- diabetes) of 9.2% (8.2%) in the population over 40 years 
of age in 2020 and 13.9% (10.2%) in 2036.
Table 2 compares Scenario 1 (no diabetes prevention pro-
gramme) with the other scenarios where the programme is 
implemented. If the prevention programme is implemented, 
the number of people with diabetes in 2036 would be pro-
jected to be reduced by between 2000 (0.5%) and 19,000 
(4.6%) depending on the scenario considered. There would 
also be an increase in the number of people with pre- diabetes 
due to the associated reduction in the transition rate in peo-
ple from pre- diabetes to diabetes. The total number of at-
tendees for the period (2022– 2036) ranges from 155,000 
to 479,000, with the cost of the programme ranging from 
€67 m to €209 m. The programme is likely to be cost reduc-
ing under two of the three scenarios with the intervention 
cost being offset by lower health care utilisation (GP, A&E, 
outpatient and inpatient) costs. Under Scenario 3, where the 
effectiveness of the programme is lower and the effects do 
not last beyond 2  years, the programme is cost increasing. 
For the people with pre- diabetes who attend the programme 
from 2022 to 2036, between 3000 and 32,000 QALYs are 




Scenarios 2−4 = iu
it
Scenario 1 ∗ 1− Intervention effectiveness ∗
Duration of effect ∗ Attendance rate )







Reduction in the transition rate from 
pre- diabetes to diabetes (%)
Scenario 1: No diabetes prevention 
programme
Scenario 2: Baseline programme 26 4 4.0 4.2
Scenario 3: Low effectiveness 13 2 4.0 1.0
Scenario 4: High attendance 26 4 12.0 12.5
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incidence of diabetes complications, with limited impact on 
the number of deaths.
4 |  DISCUSSION
Ireland does not have a national diabetes register, which 
would allow for the tracking of the number of cases of diabe-
tes over time. In this study, we simulate the trajectory of the 
number of cases of diabetes and pre- diabetes in Ireland from 
1991 to 2036 and calibrate the simulation using the available 
Irish prevalence data. Our simulation shows a dramatic rise 
in the number of cases over the period driven by a combina-
tion of an increasing population size, increases in the age- 
adjusted prevalence rates of diabetes and pre- diabetes, and 
an ageing population.
An important contribution of the paper is to highlight 
the potential impact of a diabetes prevention programme. 
Although there is significant uncertainty, the indications 
are that diabetes prevention programmes can be highly ef-
fective27 and cost- effective.28 This study shows the poten-
tial aggregate cost savings and QALY gains under various 
scenarios. Under the more optimistic scenario, there are 
small cost savings, relative to the overall cost of diabetes 
care, and material quality of life improvements; under the 
more pessimistic scenario, cost increases are small with 
fewer quality of life gains.
Key uncertainties in the potential impact of the pro-
gramme relate to attendance and effectiveness. Only a small 
proportion of eligible cases of pre- diabetes typically attend 
diabetes prevention programmes.16,17 Addressing the bar-
riers to initial and ongoing attendance to such programmes 
may significantly boost the utilisation of the service.13,29 
Attendance may be particularly low among older cohorts, 
men and people with lower levels of education.16,17 Low rates 
of referral or uptake in the latter group may exacerbate ex-
isting levels of health inequalities. Diabetes prevention pro-
grammes have been delivered through different organisation 
types (public, private and voluntary), by different individuals 
(peer volunteers and health professionals) and at different lo-
cations.30 There is limited evidence relating to the benefits of 
different organisational types and locations.31 Peer- based in-
terventions may not provide additional benefit to the general 
population32; however, they may be useful when targeting 
minority groups.
Although low attendance would reduce the overall im-
pact of the programme, this will not necessarily change the 
effectiveness or cost- effectiveness of the programme for the 
people that receive it. However, lower levels of effectiveness 
or a shorter duration of effectiveness will reduce the cost- 
effectiveness of the programme. A key challenge in the roll- 
out of the programme will be in achieving high attendance 
rates while maintaining programme effectiveness. Within the 
pre- diabetes cohort, different subgroups have different risks 
and different expectations regarding programme effective-
ness. Monitoring of programme effectiveness, including the 
reporting of attendance rates within risk subgroups, would be 
useful to ensure that high overall attendance rates are not being 
achieved at the cost of low attendance in high- risk groups. In 
addition, if there are capacity constraints in the initial stages 
of the programme, it may be worth targeting the programme 
at the groups for whom the intervention is most effective— 
for example, high body mass index (BMI) groups,13,28 with 
a focus on achieving high attendance rates in these cohorts.
Although the trajectory of the number of cases of diabetes 
will be specific to each country, the approach taken in this 
study could readily be applied to other regions. The finding 
that the impact of a diabetes prevention programme will be 
strongly influenced by attendance rates is generalisable. The 
F I G U R E  2  Fanplot of Scenario 1 projection; number of people 
with pre- diabetes (a) and diabetes (b) 1991: 2036; weighted average of 
all simulations shown in blue. Percentiles of the distribution shown in 
yellow/red.
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finding that a diabetes prevention programme will not stop 
the rise in the number of cases is also likely to be generalis-
able. As long as the stock of people in the pre- diabetes state 
continues to rise, due to population increases, population age-
ing or increases in age- adjusted prevalence of obesity, mod-
est reductions in the overall transition rate from pre- diabetes 
to diabetes will not be sufficient to stop the growth in the 
number of people with diabetes. In addition, to maintain or 
improve upon the mortality rates of people with diabetes, the 
supply of health services will need to be increased to meet the 
projected rapid growth in demand.
In addition to targeted programmes, there is a strong ra-
tionale for population- wide policies given that a large ma-
jority of people become overweight and obese; in Ireland, 
83% of men and 68% of women in the 55- to 65- year- old age 
group are overweight or obese.33 There are a wide range of 
population- wide policies relating to diet and activity that can 
be employed.34 These include policies relating to food ad-
vertising, taxes on unhealthy food and subsidies for healthy 
food. Policies to increase activity levels include urban trans-
port policy, workplace activity policies and education policy 
in schools. As with targeted interventions, population- wide 
Scenario 1: 
Reference Scenario 2 Scenario 3 Scenario 4
Difference Difference Difference
Prevalence
All 40- to 98- year- olds 2,983,807
Pre- diabetes (2036) 302,967 +4396 +1088 +14,872
Uncomplicated diabetes 
(2036)
245,639 −5820 −1442 −14,072
Complicated diabetes 
(2036)
168,725 −2049 −509 −4907
Total diabetes (2036) 414,365 −7869 −1951 −18,979
Excess health care utilisation (2036)
GP visits per year 957,544 −14,963 −3711 −36,045
A&E visits per year 51,478 −685 −170 −1647
Outpatient visits per year 510,950 −6800 −1688 −16,344
Inpatient episodes per 
year
82,363 −1122 −278 −2698















Total cost of excess 








Deaths of people with 
diabetes (2022– 2036)
87,456 −408 −100 −1247
Note: Change in the number of prevalent cases of pre- diabetes and diabetes (uncomplicated and complicated), 
change in aggregate QALYs and deaths in 2036.
Abbreviations: GP, general practitioner; QALYs, quality adjusted life years.
T A B L E  2  Impact of a diabetes 
prevention programme
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interventions requiring low levels of individual engagement, 
such as the regulation of food marketing, may have the broad-
est impact across socio- economic groups. However, there are 
very few studies that demonstrate the effectiveness of these 
programmes at a population level.19
Irrespective of the full roll- out of a diabetes preven-
tion programme, the number of people with diabetes is 
likely to be increasing rapidly in Ireland. Type 2 diabetes 
and obesity are inextricably linked.34 Previous research on 
obesity demonstrates the complex multifaceted system of 
determinants of this condition.35 Reducing the prevalence 
of obesity and diabetes is likely to require a wide range 
of policies, which each impact in a small way; a diabe-
tes prevention programme needs to be one component of 
a larger programme. A combined strategy of targeted and 
population- wide policies is likely to provide the largest re-
duction in the prevalence of diabetes19 by affecting differ-
ent cohorts and by reducing the agency required by people 
attending targeted interventions.
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